Adding ipatasertib to standard treatment for metastatic castration-resistant prostate cancer (mCRPC) significantly extended survival without disease worsening in a group of men whose tumors lack the PTEN protein, a Phase 3 clinical trial found. But the combination, which included ipatasertib plus standard Zytiga (abiraterone acetate) and prednisone/prednisolone, failed to extend the time without disease progression or death in the overall mCRPC population, the researchers noted. “The early results of the IPATential150 study are encouraging in our ongoing…
You must be logged in to read/download the full post.
The post Ipatasertib Combo Fares Well in Early Results of IPATential150 Phase 3 Study appeared first on BioNewsFeeds.